4:26 PM
 | 
Jun 21, 2019
 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease
AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting Wednesday, showing its wholly owned PD-1 agonist mAb ANB030 inhibited tetanus toxoid recall responses in human blood. AnaptysBio is also co-developing PD-1 agonist CC-90006, a Phase I candidate, with Celgene Corp. (NASDAQ:CELG); the partners are among a wave of companies seeking to exploit immuno-oncology targets for inflammatory and autoimmune diseases (see “The Flip-Side of Immunotherapy”).

Forty Seven licenses antibodies from Stanford's Weissman
Forty Seven Inc. (NASDAQ:FTSV)...

Read the full 477 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >